207 related articles for article (PubMed ID: 36185266)
1. Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer.
Rittberg R; Leung B; Al-Hashami Z; Ho C
Front Oncol; 2022; 12():1002385. PubMed ID: 36185266
[TBL] [Abstract][Full Text] [Related]
2. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
Asao T; Watanabe S; Tanaka T; Morita S; Kobayashi K
BMC Cancer; 2022 Nov; 22(1):1135. PubMed ID: 36333680
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Mathieu L; Shah S; Pai-Scherf L; Larkins E; Vallejo J; Li X; Rodriguez L; Mishra-Kalyani P; Goldberg KB; Kluetz PG; Theoret MR; Beaver JA; Pazdur R; Singh H
Oncologist; 2021 May; 26(5):433-438. PubMed ID: 33687763
[TBL] [Abstract][Full Text] [Related]
6. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data.
Wang BC; Fu C; Lin GH
Front Immunol; 2023; 14():1185577. PubMed ID: 37215120
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
[TBL] [Abstract][Full Text] [Related]
9. Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings.
Zu K; Arunachalam A; Hohlbauch A; Silver M; Robert N
Immunotherapy; 2023 Nov; 15(16):1375-1387. PubMed ID: 37694560
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
11. Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study.
Dawe DE; Rittberg R; Syed I; Shanahan MK; Moldaver D; Bucher O; Galloway K; Reynolds K; Paul JT; Harlos C; Kim JO; Banerji S
Front Oncol; 2023; 13():1191855. PubMed ID: 37795434
[TBL] [Abstract][Full Text] [Related]
12. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status.
Agarwal M; Liu A; Almquist D; Langlais BT; Leventakos K; Yu NY; Manochakian R; Ernani V
Cancer; 2023 Nov; 129(22):3546-3553. PubMed ID: 37548029
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
Inomata M; Minatoyama S; Takata N; Hayashi K; Hirai T; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Matsuyama K; Hayashi R; Matsui S; Tobe K
Anticancer Res; 2024 Mar; 44(3):1241-1245. PubMed ID: 38423671
[TBL] [Abstract][Full Text] [Related]
14. Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.
Rittberg R; Leung B; Al-Hashami Z; Ho C
Curr Oncol; 2022 Dec; 29(12):9744-9752. PubMed ID: 36547179
[TBL] [Abstract][Full Text] [Related]
15. FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.
Debieuvre D; Dayen C; Dixmier A; Pau D; Sibley-Revelat A; Greenwood W; Gally S; Falchero L
Lung Cancer; 2022 Feb; 164():1-7. PubMed ID: 34954472
[TBL] [Abstract][Full Text] [Related]
16. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
17. The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.
Choi MG; Kim YJ; Lee JC; Ji W; Oh IJ; Lee SY; Yoon SH; Lee SY; Lee JE; Kim EY; Choi CM
Cancer Res Treat; 2024 Apr; 56(2):422-429. PubMed ID: 37871898
[TBL] [Abstract][Full Text] [Related]
18. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting.
Sands J; Subramanian J
Front Oncol; 2023; 13():1161931. PubMed ID: 38221913
[TBL] [Abstract][Full Text] [Related]
19. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.
Arriola E; González-Cao M; Domine M; De Castro J; Cobo M; Bernabé R; Navarro A; Sullivan I; Trigo JM; Mosquera J; Crama L; Isla D
Oncol Ther; 2022 Jun; 10(1):167-184. PubMed ID: 35032007
[TBL] [Abstract][Full Text] [Related]
20. First-line immune-checkpoint inhibitor plus chemotherapy
Landre T; Chouahnia K; Des Guetz G; Duchemann B; Assié JB; Chouaïd C
Ther Adv Med Oncol; 2020; 12():1758835920977137. PubMed ID: 33343721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
